Latest 5-HT3 antagonist Stories
CALIFON, NJ, July 6, 2011 /PRNewswire/ - PediatRx, Inc.
LONDON, June 8, 2011 /PRNewswire/ -- - New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods The combination of palonosetron (0.25 mg iv every 48 h)...
GRANISOL's co-pay program covers patient out-of-pocket costs for non-Medicare and non-Medicaid patients CALIFON, NJ, June 1, 2011 /PRNewswire/ - PediatRx, Inc.
Oncologists report that patient out-of-pocket costs can impact form of dosage CALIFON, NJ, May 5 /PRNewswire/ - PediatRx, Inc.
Fear of nausea a significant issue and often not discussed with healthcare providers CALIFON, NJ, April 25 /PRNewswire/ - PediatRx, Inc.
Patients could instantly save up to $200 off the cost of their co-pay CALIFON, NJ, Feb. 1 /PRNewswire/ - PediatRx Inc.
CALIFON, NJ, Jan. 6 /PRNewswire/ - Hospital specialty pharmaceutical company PediatRx Inc.
In research published this week in PLoS Medicine, Stephen Freedman (University of Toronto) and colleagues performed a cost analysis of the emergency department administration of oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis and found that this treatment could provide substantial economic, as well as clinical, benefit.
NANJING, China, Aug.
WARREN, N.J. and BALERNA, Switzerland, July 7 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilmÂ® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a.
- A political dynamiter.